With the changes to #TitleX, access to contraception dramatically shifted for many low-income patients across this country this week and it's a complete shame. Access to healthcare is a human right, not a political game. Patients are not pawns. nytimes.com/2019/08/19/opi…
Providers should not be gagged when it comes to sharing information and offering care to patients. We must be able to refer them to services they need based on their individual situations. This interferes with the provider-patient relationship. nytimes.com/2019/08/19/opi…
The plan is to isolate providers offering contraception & abortion; stigmatize them out of existence. They're making it financially inaccessible for patients to go to their providers of choice for all of their reproductive healthcare. The goal is to further stigmatize abortion.
The @nytimes Editorial Board makes plain this administration's goals in stigmatizing abortion: "And that’s exactly the point for this administration: to treat abortion as though it were illegal, until perhaps that wishful thinking becomes reality." nytimes.com/2019/08/19/opi…
#TitleX has long ensured patients across the country are able to receive birth control, but many community clinics will have to leave the program simply because they offer the full spectrum of reproductive care, including abortion. This is not "pro-life." kff.org/womens-health-…
This move does nothing but undermine patients' access to healthcare and spread stigma about reproductive care and abortion, but we all know that's the goal. americanprogress.org/issues/women/r…
• • •
Missing some Tweet in this thread? You can try to
force a refresh
This peer-reviewed study looked at 2 hospitals in Texas after the 6-week abortion ban went into effect among patients presenting <22 wks with a complication like PPROM, bleeding, severe preeclampsia. sciencedirect.com/science/articl…
Since abortion was not possible, all received expectant management. Maternal morbidity occurred in 16/28 patients (57%), compared to 33% who elected immediate abortion in similar clinical situations.
I’m sure the debate tonight will be a wild ride full of misinformation about abortion. So in preparation, here are some facts from our Care Post-Roe Study documenting cases of poor-quality medical care due to bans on abortion.
We just issued an updated report from the Care Post-Roe Study, which includes 86 narratives from health care providers describing patients from 19 states with abortion bans whose care deviated from the usual standard. ansirh.org/research/resea…
More than two years since the Dobbs decision, we are continuing to receive submissions describing poor-quality care that are very similar to those we received back in 2022. More time hasn’t provided clarity around the laws.
Mifepristone is pretty awesome, and its approval by the FDA in 2000 changed the way people
obtain abortions in the US. In 2020, 53% of people having abortions in facilities had a medication
abortion with mifepristone and misoprostol.
But with mifepristone under attack in the courts, we need to figure out how we will provide abortion
care without this medication.
This thread comes from a commentary led by Beth Raymond at @Gynuity, @IbisRH, and many other authors, including @carafem, @UshmaU, and myself. It will be out shortly!
I am really proud of our Care Post Roe study and heartbroken over the stories that we're hearing coming from providers who are concerned about the legalities of treating their patients and patients who are scared to seek treatment for fear of criminalization.
In some cases, patients traveled long distances to another state to be evaluated. And sometimes it turned out they weren’t even pregnant. Sometimes it turned out they had had a miscarriage that had actually already been completed and they didn’t need any treatment.
In other cases, patients had a premature rupture of membranes in the second trimester and our standard of care would be termination. Instead, patients were being sent home and developing very severe infections that required very complicated management in the intensive care unit.
Hi @MikeKellyPA, I’m a professor of Ob/Gyn at @UCSF, an abortion provider, and researcher at @ANSIRH.
Unsurprisingly, you got a few things wrong in this tweet that I’d like to clarify. Do you mind if I outline them for you? Facts are critical when discussing medical treatments.
First, let’s address the issue of the safety of medication abortion with mifepristone. We have over 22 years of experience with this treatment, and all the data indicate that it is very safe.
For @thenation@RBraceySherman, @TracyWeitz, and I wrote about the FDA's decision to allow retail pharmacies to dispense medication abortion. While it is historic news, the fine print contains significant red tape that will continue to serve as a barrier. thenation.com/article/societ…
"Despite years of peer-reviewed, evidence-based research, the FDA chose to alter rather than eliminate the REMS for medication abortion." thenation.com/article/societ…
"The long list of requirements for pharmacy certification won’t improve the safety of medication abortion, but it will serve as a barrier to expanding the number of pharmacies that dispense mifepristone." thenation.com/article/societ…